secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0000885725-24-000060
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q2 net sales $4.12B (+14.5% reported), adj EPS $0.62, above guidance; acquires Silk Road Medical
--------------------------------------------------------------------------------

- Q2 net sales $4.120B, up 14.5% reported (16.1% operational, 14.7% organic); GAAP EPS $0.22, adjusted EPS $0.62 vs guidance $0.57-$0.59.
- Cardiovascular segment sales grew 17.8% reported; MedSurg grew 9.0%; U.S. sales up 16.9%.
- Received China NMPA approval for FARAPULSE PFA System; launched AGENT Drug-Coated Balloon in U.S. and received China NMPA approval.
- Announced agreement to acquire Silk Road Medical (SILK) for stroke prevention; subject to customary closing conditions.
- FY2024 guidance: reported sales growth 13.5-14.5%, adj EPS $2.38-$2.42; Q3 guidance: adj EPS $0.57-$0.59.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000060/0000885725-24-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572524000060/bsx-20240724.htm
  HTML page:      https://secwatch.observer/filing/0000885725-24-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer